Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 8, 2014, Pages 4877-4885

  Zou, Ming Xiang ^a   Huang, Wei ^b   Wang, Xiao Bin ^a   Lv, Guo Hua ^a   Li, Jing ^a   Deng, You Wen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Case control study; Chordoma; MicroRNA; Prognosis; Recurrence; Spine

Indexed keywords

MICRORNA; MIRN140 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; CASE CONTROL STUDY; CHORDOMA; DNA MICROARRAY; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD TUMOR;

ADULT; AGED; CASE-CONTROL STUDIES; CHORDOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; SPINAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907812490     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, Sciubba D, Gokaslan Z. Novel therapeutic targets in chordoma. Expert Opin Ther Targets 2012; 16: 1139-43.
2. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001; 12: 1-11.
3. Hu H, Yang HL, Lu J, Chen KW, Qiu YH, Liu W, Luo ZP. Association of telomerase expression with recurrence of sacral chordoma. Ann Oncol 2012; 23: 2772.
4. Horbinski C, Oakley GJ, Cieply K, Mantha GS, Nikiforova MN, Dacic S, Seethala RR. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Pathol Lab Med 2010; 134: 1170-6.
5. Medina PP, Slack FJ. MicroRNAs and cancer: an overview. Cell Cycle 2008; 7: 2485-2492.
6. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY,Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48-57.
7. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Wide-spread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-1793.
8. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381.
9. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C, Ferrari G, Ghia P, Caligaris-Cappio F. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010; 115: 3949-3959.
10. Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R, Hornicek FJ. Differential Expression of microRNA (miRNA) in Chordoma Reveals a Role for miRNA-1 in Met Expression. J Orthop Res 2010; 28: 746-52.
11. Bayrak OF, Gulluoglu S, Aydemir E, Ture U, Acar H, Atalay B, Demir Z, Sevli S, Creighton CJ, Ittmann M, Sahin F, Ozen M. MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. J Neurooncol 2013; 115: 143-51.
12. Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X, Liu Z. Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One 2013; 8: e66676.
13. Zhang Y, Schiff D, Park D, Abounader R. MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET. PLoS One 2014; 9: e91546.
14. Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F. Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. J Orthop Res 2014; 32: 695-701.
15. Goswami RS, Waldron L, Machado J, Cervigne NK, Xu W, Reis PP, Bailey DJ, Jurisica I, Crump MR, Kamel-Reid S. Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnol 2010; 10: 47-59.
16. Macabeo-Ong M, Ginzinger DG, Dekker N, Mc-Millan A, Regezi JA, Wong DT, Jordan RC. Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analy-ses. Mod Pathol 2002; 15: 979-987.
17. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixedparaffin-embedded samples. RNA 2007; 13: 1668-74.
18. Deng ZQ, Yin JY, Tang Q, Liu FQ, Qian J, Lin J, Shao R, Zhang M, He L. Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarkerdiscovery in breast cancer patients. Int J Clin Exp Pathol 2014; 7: 1166-71.
19. Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J, Ribas G. High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 2013; 463: 765-74.
20. Li X, Lu Y, Chen Y, Lu W, Xie X. MicroRNA profile of paclitaxel-resistant serous ovarian carcino-ma based on formalin-fixed paraffin-embed-ded samples. BMC Cancer 2013; 13: 216-223.
21. Fu SW, Chen L, Man YG. miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer 2011; 2: 116-22.
22. Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA, Feilotter H. An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn 2008; 10: 513-9.
23. Sand M, Skrygan M, Georgas D, Sand D, Hahn SA, Gambichler T, Altmeyer P, Bechara FG. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J Dermatol Sci 2012; 68: 119-26.
24. Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P, Bechara FG. Expression of microRNAs in basal cell carcinoma. Br J Dermatol 2012; 167: 847-55.
25. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes 2012; 5: 164.
26. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011; 17: 6802-11.
27. Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, Zhang K, Yang H. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol 2014; 31: 886.
28. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007; 12: 1344-1350.
29. Muro K, Das S, Raizer JJ. Chordomas of the craniospinal axis: multimodality surgical, radiation and medical management strategies. Expert Rev Neurother 2007; 7: 1295-1312.
30. Hoefig KP, Thorns C, Roehle A, Kaehler C, We-sche KO, Repsilber D, Branke B, Thiere M, Feller AC, Merz H. Unlocking pathology ar-chives for microRNA-profiling. Anticancer Res 2008; 28: 119-123.
31. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard B, O'Leary J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35-49.
32. Barry JJ, Jian BJ, Sughrue ME, Kane AJ, Mills SA, Tihan T, Parsa AT. The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients. Neurosurgery 2011; 68: 231-40; discussion 240-1.
33. Diaz RJ, Cusimano MD. The biological basis for modern treatment of chordoma. J Neurooncol 2011; 104: 411-22.
34. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
35. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RASRAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 103-119.